


**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (original). A phosphate compound of Formula (I)



wherein:


X represents at any available ring position -CONH-, -SO<sub>2</sub>NH-, -O-, -CH<sub>2</sub>, -NHCO- or -NHSO<sub>2</sub>-;

R represents a lower C<sub>1-6</sub> alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dialkylamino and N-oxides therefrom;

Y represents at any available ring position -N-aziridinyI, -N(CH<sub>2</sub>CH<sub>2</sub>W)<sub>2</sub> or -N(CH<sub>2</sub>CHMeW)<sub>2</sub>, where each W is independently selected from halogen or -OSO<sub>2</sub>Me.

Z represents at any available ring position -NO<sub>2</sub>, -halogen, -CN, -CF<sub>3</sub> or -SO<sub>2</sub>Me; and pharmaceutically acceptable salts and derivatives thereof.

2 (original). A phosphate compound of Formula (I) as claimed in claim 1 which is selected from a compound represented by formulae (Ia), (Ib) or (Ic)



and wherein

n represents 1 to 6

Z represents  $-\text{NO}_2$ , -halogen, -CN,  $-\text{CF}_3$  or  $-\text{SO}_2\text{Me}$ ; and

where each W is independently selected from halogen or  $-\text{OSO}_2\text{Me}$

and pharmaceutically acceptable salts and derivatives thereof.

3 (currently amended). The phosphate compound of Formula (I) as claimed

in claim 1 or claim 2 which is selected from:

2-[[2-[Bis(2-bromoethyl)amino]-3,5-dinitrobenzoyl]amino] ethyl dihydrogen phosphate;

3-[[5-[Bis(2-chloroethyl)amino]-2,4-dinitrobenzoyl]amino]propyl dihydrogen phosphate;

3-[[5-[Bis(2-bromoethyl)amino]-2,4-dinitrobenzoyl]amino]propyl dihydrogen

phosphate;

2-[[2-[Bis(2-chloroethyl)amino]-3,5-dinitrobenzoyl]amino]ethyl dihydrogen

phosphate;

2-[(2-Chloroethyl)-2,4-dinitro-6-[[[2-(phosphonooxy)ethyl]amino]-  
carbonyl]anilino]ethyl methanesulfonate;

2-({2-[Bis(2-bromopropyl)amino]-3,5-dinitrobenzoyl}amino)ethyl dihydrogen  
phosphate;

2-[(2-Bromoethyl)-2,4-dintro-6-[[[2-(phosphonooxy)ethyl]amino]-  
carbonyl]anilino]ethyl methanesulfonate;

2-[[2-[Bis(2-iodoethyl)amino]-3,5.-dinitrobenzoyl]amino]ethyl dihydrogen  
phosphate;

2-[(2-Iodoethyl)-2,4-dinitro-6-({2-phosphonooxy)ethyl]amino}carbonyl)-  
anilino]ethyl methanesulfonate;

2-[(2-Chloroethyl)-2,4-dinitro-3-[[[3-(phosphonooxy)propyl]amino]-  
carbonyl]anilino]ethyl methanesulfonate;


3-({3-[Bis(2-bromoethyl)amino]-2,6-dinitrobenzoyl}amino)propyl dihydrogen  
phosphate;

2-[(2-Bromoethyl)-2,4-dinitro-3 -[[[2-(phosphonooxy)ethyl]amino]-  
carbonyl]anilino]ethyl methanesulfonate;

2-[(2-Bromoethyl)-2,4-dinitro-3-[[[3-(phosphonooxy)propyl]amino]-  
carbonyl]anilino]ethyl methanesulfonate; and

2-[(2-Iodoethyl)-2,4-dinitro-3-[[[3-(phosphonooxy)propyl]amino]-  
carbonyl]anilino]ethyl methanesulfonate.

4 (original). A method of preparing a phosphate represented by the general formula (I);



wherein:

$\text{X}$  represents at any available ring position  $\text{—CONH—}$ ,  $\text{—SO}_2\text{NH—}$ ,  $\text{—O—}$ ,  $\text{—CH}_2\text{—}$ ,  $\text{—NHCO—}$  or  $\text{—NHSO}_2\text{—}$ ;

$\text{R}$  represents a lower  $\text{C}_{1-6}$  alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dialkylamino and N-oxides therefrom;


$\text{Y}$  represents at any available ring position  $\text{—N—aziridiny}$ l or  $\text{—N(CH}_2\text{CH}_2\text{W)}_2$ , where each  $\text{W}$  is independently selected from halogen or  $\text{—OSO}_2\text{Me}$ ;

$\text{Z}$  represents at any available ring position  $\text{—NO}_2$ ,  $\text{—halogen}$ ,  $\text{—CN}$ ,  $\text{—CF}_3$  or  $\text{—SO}_2\text{Me}$ ;

and pharmaceutically acceptable salts and derivatives thereof:

the method including the step of

(i) phosphorylating a compound of formula (II)



wherein:



X represents at any available ring position —CONH-, -SO<sub>2</sub>NH-, -O-, -CH<sub>2</sub>-,  
 -NHCO- or -NHSO<sub>2</sub>-;

Y represents at any available ring position -N-aziridinyI, -N(CH<sub>2</sub>CH<sub>2</sub>W)<sub>2</sub>, or  
 -N(CH<sub>2</sub>CH MeW)<sub>2</sub> where each W is independently selected from halogen or —OSO<sub>2</sub>Me;

Z represents at any available ring position -NO<sub>2</sub>, -halogen, -CN, -CF<sub>3</sub> or  
 -SO<sub>2</sub>Me; and

R represents a lower C<sub>1-6</sub> alkyl optionally substituted with one or more groups  
 including hydroxy, amino and N-oxides therefrom or dialkylamino and N-oxides  
 therefrom.

5 (original). A method of preparing a compound of formulae (Ia), (Ib) or (Ic)




and wherein

n represents 1 to 6

Z represents -NO<sub>2</sub>, -halogen, -CN, -CF<sub>3</sub> or -SO<sub>2</sub>Me; and

where each W is independently selected from halogen or -OSO<sub>2</sub>Me  
 and pharmaceutically acceptable salts and derivatives thereof  
 the method including the step of  
 phosphorylating a compound represented by formulae (IIa), (IIb) or (IIc)



and wherein

n represents 1 to 6

Z represents -NO<sub>2</sub>, -halogen, -CN, -CF<sub>3</sub> or -SO<sub>2</sub>Me; and

where each W is independently selected from halogen or -OSO<sub>2</sub>Me  
 and pharmaceutically acceptable salts and derivatives.

6 (original). A compound of formula (I) when obtained by the method defined in claim 4.

7 (original). A compound of formula (Ia), (Ib) or (Ic) when obtained by the method defined in claim 5.

8 (currently amended). A method of anticancer treatment including the step of administering an amount of a compound of Formula (I) as defined above in ~~any one of claims 1 to 3~~ claim 1 to a subject.

9 (currently amended). A method of killing hypoxic cells in a tumour including the step of administering an amount of a compound of Formula (I) as defined above in ~~any one of claims 1 to 3~~ claim 1 to a subject with the tumour.

10 (currently amended). The method as claimed in claim 8 ~~or claim 9~~ including the further step of applying irradiation or one or more chemotherapeutic agents to the subject.

11 (currently amended). The method as claimed in ~~any one of claims 8 to 10~~ claim 8 wherein the subject is a human.

12 (currently amended). The method as claimed in ~~any one of claims 8 to 11~~ claim 8 wherein the amount administered is between about 20% to 100% of the maximum tolerated dose of the subject.

13 (currently amended). A method of cell ablation utilising at least one nitroreductase enzyme including the step of using a compound of Formula (I) as defined above in ~~any one of claims 1 to 3~~ claim 1 in an effective amount to ablate cells which

express at least one nitroreductase enzyme.

14 (currently amended). A method of cell ablation utilising at least one nitroreductase enzyme including the step of administering a compound of Formula (I) as defined above in ~~any one of claims 1 to 3~~ claim 1 in an effective amount to a subject to ablate cells which express at least one nitroreductase enzyme.

15 (original). The method as claimed in claim 14 wherein the at least one nitroreductase enzyme is encoded for by the nfsB gene of either *E. coli* or by orthologous genes in *Clostridia* species.

16 (currently amended). The method as claimed in claim 14 ~~or claim 15~~ wherein the cells that express the at least one nitroreductase enzyme are tumour cells in tissue in the subject.

17 (currently amended). The method as claimed in ~~any one of claims 14 to 16~~ claim 14 wherein the cell ablation is achieved through GDEPT (gene-directed enzyme-prodrug therapy).

18 (currently amended). The method as claimed in ~~any one of claims 14 to 17~~ claim 14 wherein the cell ablation is achieved through ADEPT (antibody-directed enzyme-prodrug therapy).



19 (currently amended). The method as claimed in ~~any one of claims 14 to 18~~  
claim 14 wherein the cells are mammalian.

20 (currently amended). The method as claimed in ~~any one of claims 14 to 19~~  
claim 14 wherein the amount administered is between about 20% to 100% of the  
maximum tolerated dose of the subject.

21 (currently amended). The method as claimed in ~~any one of claims 14 to 20~~  
claim 14 including the further step of applying irradiation or one or more  
chemotherapeutic agents to the subject.

22 (currently amended). A pharmaceutical composition including a  
therapeutically effective amount of a compound of Formula (I) as defined in ~~any one of~~  
~~claims 1 to 3~~ claim 1 and a pharmaceutically acceptable excipient, adjuvant, carrier,  
buffer or stabiliser.

23 (currently amended). The use in the manufacture of a medicament of an  
effective amount of a compound of Formula (I) as defined in ~~any one of claims 1 to 3~~  
claim 1 to treat cancer in a subject.


24 (original). The use as claimed in claim 23 wherein the medicament is further  
adapted for use in cell ablation in conjunction with at least one nitroreductase enzyme  
including GDEPT (gene-directed enzyme-prodrug therapy) or ADEPT (antibody-directed

enzyme therapy).

25 (original). The use as claimed in 24 wherein the at least one nitroreductase enzyme is encoded for by the *nfsB* gene of either *E. coli* or by orthologous genes in *Clostridia* species.

26 (currently amended). The use as claimed in ~~any one of claims 23 to 25~~  
claim 23 wherein the medicament is adapted for a mammalian subject.

27 (original). An alcohol compound of Formula (II)



wherein:

X represents at any available ring position -CONH-, -SO<sub>2</sub>NH-, -O-, -CH<sub>2</sub>-, -NHCO- or -NHSO<sub>2</sub>-;


Y represents at any available ring position -N-aziridiny, -N(CH<sub>2</sub>CH<sub>2</sub>W)<sub>2</sub>, or -N(CH<sub>2</sub>CH MeW)<sub>2</sub> where each W is independently selected from halogen or -OSO<sub>2</sub>Me;

Z represents at any available ring position -NO<sub>2</sub>, -halogen, -CN, -CF<sub>3</sub> or -SO<sub>2</sub>Me;

R represents a lower C<sub>1-6</sub> alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dialkylamino and N-oxides



therefrom; and pharmaceutically acceptable salts and derivatives thereof; with the proviso that

when Z represents  $\text{NO}_2$  and Y represents  $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$ , X and R together cannot represent  $-\text{CONHCH}_2(\text{CHOH})\text{CH}_2-$  and with the further proviso that the following compounds



are excluded.

28 (original). The alcohol compound of Formula (II) as claimed in claim 27  
 selected from a compound represented by formulae (IIa), (IIb) or (IIc)




and wherein


n represents 1 to 6

Z represents -NO<sub>2</sub>, -halogen, -CN, -CF<sub>3</sub> or -SO<sub>2</sub>Me; and

where each W is independently selected from halogen or -OSO<sub>2</sub>Me and  
 pharmaceutically acceptable salts and derivatives thereof with the proviso that

when Z represents NO<sub>2</sub> and Y represents N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>, X and R together  
 cannot represent -CONHCH<sub>2</sub>(CHOH)CH<sub>2</sub>- and with the further proviso that the following  
 compounds





are excluded.

29 (original). The alcohol compound of Formula (II) selected from a compound of Formula (IIb) or (IIc) as defined in claim 28.

30 (currently amended). The alcohol compound of Formula (II) as defined in claim 28 or claim 29 selected from:

N-(2-Hydroxyethyl)-5-[bis(2-bromooethyl)amino]-2,4-dinitrobenzamide;

N-(4-Hydroxybutyl)-5-[bis(2-bromoethyl)amino]-2,4-dinitrobenzamide;

N-(5-Hydroxypentyl)-5-[bis(2-bromoethyl)amino]-2,4-dinitrobenzamide;

N-(6-Hydroxyhexyl)-5-[bis(2-bromoethyl)amino]-2,4-dinitrobenzamide;

5-[Bis(2-bromoethyl)amino]-N-(2-hydroxyethyl)-4-(methylsulfonyl)-2-nitrobenzamide;

2[(2-Bromoethyl)-5-[(3-hydroxypropyl)amino]carbonyl]-2,4-dinitroanilino)ethyl methanesulfonate;

5-[Bis(2-iodoethyl)amino]-N-(2-hydroxyethyl)-2,4-dinitrobenzamide;

2-[Bis(2-Chloroethyl)amino]-N-(2-hydroxyethyl)-3,5-dinitrobenzamide;

2-[Bis(2-bromoethyl)amino]-N-(2-hydroxyethyl)-3,5-dinitrobenzamide;

2-[Bis(2-chloroethyl)amino]-N-(3-hydroxypropyl)-3,5-dinitrobenzamide;

2-[Bis(2-bromoethyl)amino]-N-(3-hydroxypropyl)-3,5-dinitrobenzamide;

2-[Bis(2-chloroethyl)amino]-N-(4-hydroxybutyl)-3,5-dinitrobenzamide,

2-[Bis(2-bromoethyl)amino]-N-(4-hydroxybutyl)-3,5-dinitrobenzamide;

2-[Bis(2-chloroethyl)amino]-N-(5-hydroxypentyl)-3,5-dinitrobenzamide,

2-[Bis(2-bromoethyl)amino]-N-(5-hydroxypentyl)-3,5-dinitrobenzamide;

2-[Bis(2-chloroethyl)amino]-N-(6-hydroxyhexyl)-3,5-dinitrobenzamide;

2-[Bis(2-bromoethyl)amino]-N-(6-hydroxyhexyl)-3,5-dinitrobenzamide;

2-[Bis(2-bromopropyl)amino]-N-(2-hydroxyethyl)-3,5-dinitrobenzamide;

2-((2-Bromoethyl)-2-[(2-hydroxypropyl)amino]carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate;

2-((2-Bromoethyl)-2-[(2-hydroxyethyl)amino]carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate;

2-((2-Chloroethyl)-2-[(2-hydroxyethyl)amino]carbonyl)-4,6-dinitroanilino)ethyl

methanesulfonate;

2-[Bis(2-iodoethyl)amino]-N-(2-hydroxyethyl)-3,5-dinitrobenzamide;

2-((2-iodoethyl)-2-(((2-hydroxyethyl)amino)carbonyl))-4,6-dinitroanilino)ethyl

methanesulfonate;

3-[Bis(2-bromoethyl)amino]-N-(2-hydroxyethyl)-2,6-dinitrobenzamide;

2-((2-bromoethyl)-3-(((2-hydroxyethyl)amino)carbonyl))-2,4-dinitroanilino)ethyl

methanesulfonate;

3-[Bis(2-bromoethyl)amino]-N-(3-hydroxypropyl)-2,6-dinitrobenzamide;

2-((2-bromoethyl)-3-(((3-hydroxypropyl)amino)carbonyl))-2,4-dinitroanilino)ethyl

methanesulfonate;

3-[Bis(2-bromoethyl)amino]-N-(4-hydroxybutyl)-2,6-dinitrobenzamide;

2-((2-bromoethyl)-3-(((4-hydroxybutyl)amino)carbonyl))-2,4-dinitroanilino)ethyl

methanesulfonate;


2-((2-chloroethyl)-3-(((3-hydroxypropyl)amino)carbonyl))-2,4-dinitroanilino)ethyl

methanesulfonate; and


2-((2-iodoethyl)-3-(((3-hydroxypropyl)amino)carbonyl))-2,4-dinitroanilino)ethyl

methanesulfonate.


31 (original). A method of preparing a compound of formulae (IIa), (IIb) or (IIc)



(IIa)




(IIb)



(IIc)

wherein Y may represent



and wherein

n represents 1 to 6

Z represents -NO<sub>2</sub>, -halogen, -CN, -CF<sub>3</sub> or -SO<sub>2</sub>Me; and


where W<sub>1</sub> is halogen and W<sub>2</sub> is -OSO<sub>2</sub>Me

and pharmaceutically acceptable salts and derivatives thereof;

the method including the step of

reacting a compound of formulae (IIa'), (IIb') or (IIc') optionally with heating





wherein W<sub>1</sub> and W<sub>2</sub> are each halogen;

with an effective amount of silver methanesulfonate (AgOMs) in a solvent to give a compound of formulae (IIa), (IIb) or (IIc) defined above in this claim.

32 (original). The method as claimed in claim 31 wherein the solvent is selected from MeCN or other polar non-protic solvent.

33. (currently amended). A compound of formula (IIa), (IIb) or (IIc) obtained by the method defined in claim 31 or claim 33.

34 (original). A method of anticancer treatment including the step of administering an amount of a compound of Formula (II) as defined in claim 27 to a subject.

35 (original). A method of killing hypoxic cells in a tumour including the step of administering an amount of a compound of Formula (II) as defined in claim 27 to a subject with the tumour,

36 (currently amended). The method as claimed in claim 34 ~~or claim 35~~ including the further step of applying irradiation or one or more chemotherapeutic agents to the subject.

37 (currently amended). The method as claimed in ~~any one of claims 34 to 36~~ claim 34 wherein the subject is a human.

38 (original). A method of cell ablation utilising at least one nitroreductase enzyme including the step of using a compound of Formula (II) as defined in claim 27 in an effective amount to ablate cells which express at least one nitroreductase enzyme.

39 (original). A method of cell ablation utilising at least one nitroreductase enzyme including the step of administering a compound of Formula (II) as defined in claim 27 in an effective amount to a subject to ablate cells which express at least one nitroreductase enzyme.

40 (original). The method as claimed in claim 39 wherein the at least one nitroreductase enzyme is encoded for by the nfsB gene of either *E. coli* or by orthologous genes in *Clostridia* species.

41 (currently amended). The method as claimed in claim 39 ~~or claim 40~~ wherein the cells that express the at least one nitroreductase enzyme are tumour cells in tissue in the subject.

42 (currently amended). The method as claimed in ~~any one of claims 39 to 41~~ claim 39 wherein the cell ablation is achieved through GDEPT (gene-directed enzyme-prodrug therapy).

43 (currently amended). The method as claimed in ~~any one of claims 39 to 41~~ claim 39 wherein the cell ablation is achieved through ADEPT (antibody-directed enzyme-prodrug therapy).

44 (currently amended). The method as claimed in ~~any one of claims 39 to 43~~ claim 39 wherein the cells are mammalian.

45 (currently amended). The method as claimed in ~~any one of claims 39 to 44~~ claim 39 including the thither step of applying irradiation or one or more chemotherapeutic agents to the subject.

46 (original). A pharmaceutical composition including a therapeutically effective amount of a compound of Formula (II) as claimed in claim 27 and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.

47 (original). The use in the manufacture of a medicament of an effective amount of a compound of Formula (II) as claimed in claim 27 as an anticancer agent in a subject.

48 (original). The use as claimed in claim 47 wherein the medicament is further adapted for use in cell ablation in conjunction with at least one nitroreductase enzyme including GDEPT (gene-directed enzyme-prodrug therapy) or ADEPT (antibody-directed enzyme therapy).

49 (original). The use as claimed in claim 48 wherein the at least one nitroreductase enzyme is encoded for by the *nfsB* gene of either *E. coli* or by orthologous genes in *Clostridia* species.

50 (currently amended). The use as claimed in ~~any one of claims 47 to 49~~  
claim 47 wherein the medicament is adapted for a mammalian subject.

51 (new). A compound selected from:

2-[(2-Bromoethyl)-2,4-dinitro-6-[[[2-(phosphonooxy)ethyl]amino]-  
carbonyl]anilino]ethyl methanesulfonate;

2-[(2-Bromoethyl)-2,4-dinitro-3-[[[2-(phosphonooxy)ethyl]amino]-  
carbonyl]anilino]ethyl methanesulfonate;

2-[(2-Bromoethyl)-2,4-dinitro-3-[[[3-(phosphonooxy)propyl]amino]-

carbonyl]anilino]ethyl methanesulfonate; and

2-[(2-Iodoethyl)-2,4-dinitro-3-[[[3-(phosphonooxy)propyl]amino]-  
carbonyl]anilino]ethyl methanesulfonate.

52 (new). The compound

2-[(2-Bromoethyl)-2,4-dinitro-6-[[[2-(phosphonooxy)ethyl]amino]-  
carbonyl]anilino]ethyl methanesulfonate.

53 (new). A pharmaceutical composition including a therapeutically effective amount of a compound as claimed in claim 51 or claim 52 and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.

54-56 (cancelled).

57 (new). A method of cell ablation utilising at least one nitroreductase enzyme including the step of using a compound as defined above in claim 51 or claim 52 in an effective amount to ablate cells which express at least one nitroreductase enzyme, with the proviso that when the cells are human cells they are ex-vivo cells.

58-64 (cancelled).